For Pediatric Patients, Wearable Cardioverter Defibrillator Safe

This article originally appeared here.
Share this content:
For Pediatric Patients, Wearable Cardioverter Defibrillator Safe
For Pediatric Patients, Wearable Cardioverter Defibrillator Safe

TUESDAY, June 26, 2018 (HealthDay News) -- For pediatric patients with ventricular arrhythmias at risk for sudden cardiac death (SCD), a wearable cardioverter defibrillator (WCD) seems safe and effective, according to a review published online June 26 in Circulation: Arrhythmia and Electrophysiology.

David S. Spar, M.D., from Cincinnati Children's Hospital Medical Center, and colleagues conducted a retrospective review of all U.S. pediatric patients younger than 18 years who wore a WCD from 2009 to 2016. A total of 455 patients were identified: 63 patients with an implantable cardioverter defibrillator (ICD) problem and 392 with a non-ICD problem.

The researchers found that for both groups of patients, wear time per day was above 20 hours. The ICD problem group had shorter wear duration (26 versus 35 days). Seven deaths (1.5 percent) were recorded; all were not wearing WCD at the time of death. At least one WCD shock treatment was received by eight patients (1.8 percent). Of the six patients (1.3 percent) with appropriate therapy, seven episodes of either polymorphic ventricular tachycardia or ventricular fibrillation were recorded with 13 treatments delivered. Successful conversion of all episodes occurred and the patients survived.

"The WCD has overall adequate compliance with appropriate wear times and wear durations in pediatric patients. The WCD is safe and effective in treating ventricular arrhythmias that can lead to SCD in pediatric patients," the authors write.

One author is an employee of ZOLL.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »